NCT07551635
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 55 words
- Start date changed from estimate of Sep 4, 2026 to Apr 28, 2026
- Secondary endpoints: details revised at 4 of 5 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: Observed on treatment; Time frame is variable by patient as duration of treatment is event-driven per protocol section 5.5. Disease assessed on treatment every 2 cycles (cycle duration=21 days). Response follow-up expected up to 12 months.
Secondary (5)
Median Progression-Free Survival (PFS)
Median Overall Survival
Median Time-To-Progression (TTP)
Median Duration of Response (DOR)
Treatment-Related Grade 3-4 Adverse Event (AE) Rate
Arms and interventions
FHD-286Experimental
* Baseline visit * Cycle 1 through End of Treatment (21-day cycles) * Days 1 - 21: Predetermined dose of FHD-286 1X daily. Possible dose escalation or based on tolerability. * 30 day follow up post-treatment discontinuation * Annual follow up for up to 5 years.
Drugs: FHD-286
Sites
1 site in 1 country
- Dana-Farber Cancer InstituteBoston, Massachusetts, United States